Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Drug: ABBV-1088
ABBV-1088 · 1 trial · 1 indication
Cmax of ABBV-1088
Tmax of ABBV-1088
Terminal phase elimination rate constant (beta) of ABBV-1088
Terminal phase elimination half-life of ABBV-1088
AUCt of ABBV-1088
AUCinf of ABBV-1088
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study
| Arm | Type | Description |
|---|---|---|
| Group 1- ABBV-1088 Dose A | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose A on day 1 |
| Group 1- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 2- ABBV-1088 Dose B | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose B on day 1 |
| Group 2- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 3- ABBV-1088 Dose C | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose C on day 1 |
| Group 3- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 4- ABBV-1088 Dose D | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose D on day 1 |
| Group 4- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 5- ABBV-1088 Dose E | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose E on day 1 |
| Group 5- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Group 6- ABBV-1088 Dose F | EXPERIMENTAL | Participants will receive single dose of ABBV-1088 dose F on day 1 |
| Group 6- Placebo | EXPERIMENTAL | Participants will receive single dose of placebo day 1 |
| Name | Type | Description |
|---|---|---|
| Drug: ABBV-1088 | DRUG | • Oral Capsule |
| Drug: Placebo for ABBV-1088 | DRUG | • Oral Capsule |
Inclusion Criteria: * BMI is ≥ 18.0 to ≤ 32.0 kg/m\^2 after rounding to the tenths decimal at screening. * A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG Exclusion Criteria: * History of card...
ABBV-1088 is an investigational small molecule drug developed by AbbVie Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers to assess its safety, tolerability, and pharmacokinetics. It is not approved for any indication and remains in clinical development.
ABBV-1088 is not approved for any medical use. It has been tested only in healthy volunteers as part of a Phase 1 study, not in patients with a specific disease. Its potential therapeutic applications have not been established.
ABBV-1088 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical program for this investigational small molecule.
ABBV-1088 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug has not received FDA approval and remains investigational.
ABBV-1088 has been evaluated in one completed Phase 1 trial, NCT06414798, titled "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants." The trial enrolled 60 healthy adults in the United States and was randomized, double-blind, and controlled.
Yes, ABBV-1088 is also referred to as Drug: ABBV-1088. Both names refer to the same investigational small molecule developed by AbbVie Inc. for study in healthy volunteers.